<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823208</url>
  </required_header>
  <id_info>
    <org_study_id>17609</org_study_id>
    <secondary_id>J1I-JE-GZBC</secondary_id>
    <nct_id>NCT04823208</nct_id>
  </id_info>
  <brief_title>A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn about the side effects of LY3437943 when given to&#xD;
      Japanese participants with type 2 diabetes mellitus. Blood tests will be performed to&#xD;
      investigate how the body processes the study drug and how the study drug affects the body.&#xD;
      Each enrolled participant will receive injections of LY3437943 or placebo given just under&#xD;
      the skin. For each participant, the study will last up to 5 months, inclusive of screening&#xD;
      and will include 16 visits to the study center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">April 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 6, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 106</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943</measure>
    <time_frame>Predose on Day 1 through Day 81</time_frame>
    <description>PK: Cmax of LY3437943</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3437943</measure>
    <time_frame>Predose on Day 1 through Day 81</time_frame>
    <description>PK: AUC of LY3437943</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean Daily Plasma Glucose (PG)</measure>
    <time_frame>Baseline through Day 80</time_frame>
    <description>Change from baseline in mean daily PG from 6-point PG profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Glycated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline through Day 78</time_frame>
    <description>Change from Baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Glucose</measure>
    <time_frame>Baseline through Day 78</time_frame>
    <description>Change from Baseline in Fasting Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline through Day 78</time_frame>
    <description>Change from Baseline in Body Weight</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY3437943</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3437943</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3437943</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year.&#xD;
&#xD;
          -  Have glycated hemoglobin (HbA1c) value ≥ 7.0% and ≤10.0% for participants treated with&#xD;
             diet and exercise or HbA1c ≥ 6.5% and ≤ 9.0% for participants who have washed out&#xD;
             antidiabetic medications at lead-in and screening&#xD;
&#xD;
          -  Have a body mass index (BMI) within the range 23 to 35 kilograms per square meter&#xD;
             (kg/m²), inclusive, and a body weight of at least 54 kilograms (Kg).&#xD;
&#xD;
          -  Males and females not of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have type 1 diabetes mellitus (T1DM)&#xD;
&#xD;
          -  Have uncontrolled diabetes defined as an episode of ketoacidosis or hyperosmolar state&#xD;
             requiring hospitalization&#xD;
&#xD;
          -  Have had an episode of severe hypoglycemia, as defined by the occurrence of&#xD;
             neuroglycopenic symptoms requiring the assistance of another person for recovery, or&#xD;
             have a history of hypoglycemia unawareness or poor recognition of hypoglycemic&#xD;
             symptoms.&#xD;
&#xD;
          -  Have a history of acute or chronic pancreatitis or fasting serum triglyceride level of&#xD;
             &gt;500 milligram per deciliter (mg/dL).&#xD;
&#xD;
          -  Have known liver disease, obvious clinical signs or symptoms of liver disease, acute&#xD;
             or chronic hepatitis, or have elevations in aminotransferases (alanine&#xD;
             aminotransferase [ALT] and aspartate aminotransferase [AST]) greater than 3× upper&#xD;
             limit of normal (ULN).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OCROM Clinic</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0663308810</phone>
    </contact>
    <investigator>
      <last_name>Satoshi Inoue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P-one clinic</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81426255216</phone>
    </contact>
    <investigator>
      <last_name>Kenichi Furihata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Hospital Tokyo</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>03-3355-7200</phone>
    </contact>
    <investigator>
      <last_name>Hiroyuki Fukase</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokohama Minoru Clinic</name>
      <address>
        <city>Yokohama</city>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81457228655</phone>
    </contact>
    <investigator>
      <last_name>Keitoku Matsumoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/7kfc2KQV7TAO767FQsfZMZ</url>
    <description>A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)</description>
  </link>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

